ADAR1 Capital Management »

Tourmaline Bio shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Tourmaline Bio (TRML) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Tourmaline Bio

Tip: Access up to 7 years of quarterly data

All positions including Tourmaline Bio held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tourmaline Bio by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $265k 12k 22.90

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Tourmaline Bio

Blue Owl Capital Holdings
Cormorant Asset Management
Jennison Associates
QVT Financial
Vanguard Group
Braidwell
venBio Select Advisor
Nantahala Capital Management
Qiming U.S. Ventures Management
Vivo Capital
BlackRock
Darwin Global Management
Eventide Asset Management
Velan Capital Investment Management
Artal Group

View all funds holding Tourmaline Bio